Evidence map›Paper›PMID 36765785›Full record

ArticleCancers2023

Flexible Cyclic Immunofluorescence (cyCIF) Using Oligonucleotide Barcoded Antibodies.

Nathan P McMahon, Jocelyn A Jones, Ashley N Anderson, Matthew S Dietz, Melissa H Wong, Summer L Gibbs

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Theranostics · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nathan P McMahonBiomedical Engineering Department, Oregon Health & Science University, Portland, OR 97201, USA.
Jocelyn A JonesBiomedical Engineering Department, Oregon Health & Science University, Portland, OR 97201, USA.
Ashley N AndersonDepartment of Cell, Development & Cancer Biology Department, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0002-7522-846X
Matthew S DietzDepartment of Cell, Development & Cancer Biology Department, Oregon Health & Science University, Portland, OR 97201, USA.
Melissa H WongDepartment of Cell, Development & Cancer Biology Department, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0002-5127-279X
Summer L GibbsBiomedical Engineering Department, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0001-8077-1582
Oregon Health & Science University · US

Funding

Oregon Clinical and Translational Research Institute TL1 ProgramTL1TR002371 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ALLISON Deborah FRYER, JESSINA C MCGREGOR · 2017 to 2026
$6.2M
Mechanistic understanding of the lifecycle of a circulating hybrid cell.R01CA260196 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GIBBS, SUMMER LYNNE, WONG, MELISSA H. · 2021 to 2025
$3.2M
Mechanisms of Neoplastic Hybrid Cell Dissemination in Colorectal CancerF31CA271676 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ANDERSON, ASHLEY NICOLE · 2022 to 2025
$168k
NCATS NIH HHS TL1 TR002371NCATS NIH HHS TL1TR002371NCI NIH HHS F31 CA271676NCI NIH HHS F31CA271676-01NCI NIH HHS R01 CA260196NCI NIH HHS R01CA260196
6 · The paper itself

Abstract

Advances in our understanding of the complex, multifaceted interactions between tumor epithelia, immune infiltrate, and tumor microenvironmental cells have been driven by highly multiplexed imaging technologies. These techniques are capable of labeling many more biomarkers than conventional immunostaining methods. However, multiplexed imaging techniques suffer from low detection sensitivity, cell loss-particularly in fragile samples-, and challenges with antibody labeling. Herein, we developed and optimized an oligonucleotide antibody barcoding strategy for cyclic immunofluorescence (cyCIF) that can be amplified to increase the detection efficiency of low-abundance antigens. Stained fluorescence signals can be readily removed using ultraviolet light treatment, preserving tissue and fragile cell sample integrity. We also extended the oligonucleotide barcoding strategy to secondary antibodies to enable the inclusion of difficult-to-label primary antibodies in a cyCIF panel. Using both the amplification oligonucleotides to label DNA barcoded antibodies and in situ hybridization of multiple fluorescently labeled oligonucleotides resulted in signal amplification and increased signal-to-background ratios. This procedure was optimized through the examination of staining parameters including staining oligonucleotide concentration, staining temperature, and oligonucleotide sequence design, resulting in a robust amplification technique. As a proof-of-concept, we demonstrate the flexibility of our cyCIF strategy by simultaneously imaging with the original oligonucleotide conjugated antibody (Ab-oligo) cyCIF strategy, the novel Ab-oligo cyCIF amplification strategy, as well as direct and indirect immunofluorescence to generate highly multiplexed images.

Indexed as

cyclic immunofluorescence (cyCIF)DNA barcoded antibodiesphotocleavable linkersspatial proteomics

Identifiers

PMID36765785
PMCPMC9913741
OpenAlexW4318486447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.